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OBJECTIVES The aim of our study was to explore evolving changes in a mitral flow velocity pattern
(MFVP) and its hemodynamic and pathological correlates in hypertensive rats in an isolated
diastolic heart failure model.
BACKGROUND Development of left ventricular (LV) hypertrophy and concomitant diastolic dysfunction
cause heart failure in hypertensive hearts even with normal systolic function; however,
associated evolving change in MFVP is still unclear.
METHODS Mitral flow velocity pattern was recorded every 2 weeks from 7 to 19 weeks in six hypertensive
rats. Hemodynamic and pathological correlates of Doppler mitral flow indexes were examined
as an additional part of the study using the hypertensive rats at the age of 13 weeks
(compensatory stage, n 5 7) and at 19 weeks (heart failure stage, n 5 8).
RESULTS Initial development of pressure overload LV hypertrophy resulted in a decrease in early
diastolic filling wave (E), a reciprocal increase in the filling wave due to atrial contraction (A)
and prolongation of deceleration time of E wave (relaxation abnormality pattern). These
changes were associated with an increase in tau, an index of LV relaxation, but without a
change in LV end-diastolic pressure. Transition to congestive heart failure caused an increase
in E, a decrease in A and shortening of deceleration time. These changes were not associated
with further increase in tau but with elevation of LV end-diastolic pressure, reflecting marked
LV hypertrophy and myocardial fibrosis.
CONCLUSIONS Development of pressure overload LV hypertrophy is associated with evolving changes in
MFVP from normal to relaxation abnormality pattern and, in turn, to pseudonormalized to
restrictive pattern. Analysis of MFVP may be useful to follow not only functional but also
constitutional changes of the myocardium in hypertensive hearts. (J Am Coll Cardiol 2000;
36:2333–8) © 2000 by the American College of Cardiology
Progressive left ventricular (LV) hypertrophy (LVH) and
associated diastolic dysfunction are considered to alter
Doppler mitral flow velocity pattern (MFVP) from a normal
to a relaxation abnormality pattern and, in turn, to a
pseudonormalized pattern and finally to a restrictive pattern
(1–4). This idea is mainly based on the data of a number of
clinical comparative studies in which MFVP was correlated
to symptomatic or hemodynamic severity of the disease
among patients. Longitudinal studies over the natural
course have not been done so far in patients with hyperten-
sion because the disease process usually requires decades.
Some longitudinal experimental works exist in which devel-
opmental LVH caused alteration in the LV filling pattern
from normal to a relaxation abnormality pattern (5,6), but
any of these works only observed initial changes and failed
to observe the later change, i.e., alteration to a pseudonor-
malized or a restrictive pattern. Litwin et al. (7) performed
longitudinal studies in rats with pressure-overload LVH till
heart failure occurs; however, the relaxation abnormality
pattern was not detected, probably because progressive LV
systolic dysfunction was concomitant in their model. In
human patients with hypertension, LV dysfunction is lim-
ited in diastole, at least in the initial stage, and the difference
in the type of evolving LV dysfunction may account for the
difference in the evolving changes in the MFVP. Thus, it
would be interesting if we could study the evolving change
in MFVP in a model of isolated diastolic heart failure.
We have recently established an isolated diastolic heart
failure model using Dahl salt-sensitive hypertensive rats, in
which hypertension develops with LVH and diastolic dys-
function but without LV systolic dysfunction throughout
the natural course (8). With normal LV systolic function,
the rats fall into congestive heart failure due to isolated
diastolic dysfunction. In the previous models of pressure,
overload LVH ultimately becoming congestive heart failure
marked systolic dysfunction was concomitant (7,9–11).
Compared with these models our model is considered more
adequate to study the chronic effects of the development of
LVH and the concomitant diastolic dysfunction on MFVP
because no, or only minimal, systolic dysfunction is observed
even in the failing stage. This model was used in this study
to explore evolving changes in MFVP associated with the
development of LVH and concomitant diastolic dysfunc-
tion until isolated diastolic heart failure occurs. Hemody-
namic and pathological correlates of evolving changes in
MFVP were also studied in the subgroup.
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METHODS
This study conforms to the guiding principles of the Osaka
University Graduate School of Medicine with regard to
animal care and to the position of the American Heart
Association on research animal use.
Subjects. This study consists of two parts, but both parts
were performed using our recently developed rat models of
isolated diastolic heart failure (8). Laboratory chow contain-
ing 0.3% NaCl was continuously fed to the male Dahl-Iwai
salt-sensitive (Dahl S) rats (DIS/Eis, Eisai, Tokyo, Japan)
(control rats). If the diet is switched to laboratory chow
containing 8% NaCl at 7 weeks old, the rats die at 19 weeks
or so with marked concentric LVH, severe pulmonary
edema and elevated LV end-diastolic pressure (LVEDP)
but with normal or minimally impaired LV systolic function
(diastolic failure model).
The first part of the study (evolution study) was done in
six rats of diastolic failure model and six control rats. In
these rats echocardiographic Doppler studies were repeated
at the ages of 7, 9, 11, 13, 15, 17, 19 weeks, and no other
study was done. The second part of the study (hemodynam-
ic and pathological study) was done in 16 control rats at the
ages of 7, 13 or 19 weeks (n 5 4, 7 and 5, respectively) and
in 15 rats of the diastolic failure model at the ages of 13 or
19 weeks (n 5 7 and 8, respectively). These rats were
sacrificed after echocardiographic Doppler and hemody-
namic studies to obtain pathologic parameters. There was
no overlap in rats between the first and second parts of the
study.
Echocardiographic Doppler studies. Transthoracic of
M-mode LV echogram and MFVP were obtained with an
echocardiograph equipped with a 7.5 MHz transducer
(SONOS 2000, Hewlett-Packard, Andover, Massachu-
setts) after anesthetization with intraperitoneal administra-
tion of ketamine HCl (50 mg/kg) and xylazine HCl
(10 mg/kg) using the method previously described (8).
Anterior and posterior wall thickness and LV internal
dimension were measured at end-diastole and at end-systole
using a modification of the American Society for Echocar-
diography leading edge method (12). Midwall fractional
shortenings and LV mass were calculated as previously
described (8,13). Left ventricular mass was presented as the
ratio to body weight (mg/g). Mitral flow velocity pattern
was provided for determination of peak early diastolic filling
velocity (E velocity), peak filling velocity at atrial contrac-
tion (A velocity), their ratio (E/A ratio) and the deceleration
time (DT) of early diastolic filling wave (Fig. 1).
Hemodynamic studies. A high-fidelity LV pressure curve
was obtained and analyzed using a previously described
method (8,13). The data were digitized at a rate of 2,000
samples per second for the determination of systolic and
end-diastolic pressure, peak positive and negative value of
its first derivatives (dP/dt) and an index of LV relaxation,
tau, using a nonzero asymptote method.
Left ventricular pressure and LV M-mode echogram
were simultaneously recorded in all rats except 13-week-old
control rats to determine myocardial stiffness constant
(MSC) as previously described (14). In this analysis, the
s-ln (1/H) relation of the LV regional wall was evaluated with
a spherical model of the ventricle to calculate mean wall stress
(s) using the equation: s 5 PD/4H, where P is LV pressure,
D is LV short axis diameter and H is wall thickness of the
region of interest. Specifically, hand-traced lines of LV pres-
sure and M-mode echograms were scanned into a computer
system (Power Macintosh 7600/120, Apple, California), and
the lines were digitized at a rate of 40 samples per cardiac cycle
to obtain the curves of LV pressure, internal diameter and
wall thickness. The diastolic s-ln (1/H) data points from
the point of minimal wall stress to the point at end-diastole
were fitted to a single exponential curve with zero asymp-
tote: s 5 C exp [K ln (1/H)], where K was determined as
an MSC in the anterior and posterior walls.
Randomly selected, 10 recordings were used to assess
reproducibility of the measurements of MSC. Two observ-
ers independently analyzed the same recording to determine
MSC (interobserver variability). Intraobserver variability
was determined by one observer repeating the analysis
process a second time for comparison with his first mea-
surements. Mean differences between observations were
0.00 6 0.25 (interobserver) and 0.01 6 0.14 (intraobserver),
and absolute differences between observations were 0.19 6
0.13 (interobserver) and 0.11 6 0.08 (intraobserver).
Abbreviations and Acronyms
A 5 filling wave due to atrial contraction
dP/dt 5 first derivatives of left ventricular value of
systolic and end-diastolic pressure
DT 5 deceleration time of early diastolic filling
wave
E 5 early diastolic filling wave
E/A ratio 5 the ratio of peak early diastolic filling
velocity and peak filling velocity at atrial
contraction
LV 5 left ventricular
LVEDP 5 left ventricular end-diastolic pressure
LVH 5 left ventricular hypertrophy
MFVP 5 mitral flow velocity pattern
MSC 5 myocardial stiffness constant
Figure 1. Evolving mitral flow velocity patterns in hypertensive rat. See
text for explanation. A 5 filling wave due to atrial contraction; E 5 early
diastolic filling wave.
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Pathological studies. Hemodynamic studies were followed
by adequate additional anesthesia; an incision was made in
the chest, and the LV was harvested and weighed. Speci-
mens of the LV were provided to determine myocyte
diameter and the percent area of fibrosis as previously
described (8,13).
Statistical analysis. Results are expressed as mean values 6
standard deviation. Data were analyzed using a statistical
software (STATVIEW II, Abacus Concepatients, Berkeley,
California). Differences between stages were assessed using
one-factor analysis of variance and Scheffe’s test for factorial
analysis. Differences between two groups were assessed
using Student t test. A p value of less than 0.01 was
considered statistically significant.
RESULTS
Echocardiographic Doppler parameters. Blood pressure
increased from 7 to 13 weeks; thereafter, it was constant,
and LV mass gradually increased from 7 to 19 weeks in
hypertensive rats (Table 1). Left ventricular end-diastolic
dimension was smaller in hypertensive rats than it was in
control rats between 9 and 17 weeks, but midwall fractional
shortening was not different between hypertensive and
controls rats throughout the experiment. Early diastolic
filling wave and E/A ratio slightly and progressively de-
creased from 7 to 11 weeks and were almost constant
between 11 and 15 weeks, followed by an abrupt increase at
15 or 17 weeks (Fig. 2). Deceleration time was prolonged
from 7 to 11 weeks, and, thereafter, it was gradually
shortened (Fig. 3).
Hemodynamic and pathological correlates. Elevation of
LVEDP was observed at 19 weeks in hypertensive rats
(Table 2, Fig. 4). Tau was increased at 13 weeks in
hypertensive rats, but there was no further increase in tau
after that. Myocardial stiffness constant did not change at 13
weeks but significantly increased at 19 weeks at the anterior
and posterior walls. There was a progressive increase in
myocyte diameter in hypertensive rats, but significant myo-
cardial fibrosis was evident only at 19 weeks in hypertensive
rats.
DISCUSSION
Mitral flow velocity pattern changed from normal to relax-
ation abnormality pattern with initial development of LVH
and associated diastolic dysfunction. This change was asso-
ciated with myocardial hypertrophy but not with myocardial
fibrosis, and LV functional alteration was exclusively ob-
served in the LV relaxation phase. Advanced development
Table 1. Serial Changes in Echocardiographic Parameters in Control and Hypertensive Rats
Group 7 Weeks 9 Weeks 11 Weeks 13 Weeks 15 Weeks 17 Weeks 19 Weeks
Systolic blood pressure (mm Hg)
Control 123 6 6 121 6 6 132 6 10 144 6 9 129 6 8 146 6 8 146 6 8
Hypertension 120 6 7 166 6 15* 197 6 13* 235 6 5* 233 6 7* 236 6 6* 231 6 7*
Heart rate (beats per minute)
Control 238 6 15 217 6 12 239 6 20 226 6 11 228 6 13 215 6 11 235 6 22
Hypertension 229 6 14 241 6 17 229 6 10 231 6 21 227 6 18 240 6 14 241 6 21
End-diastolic dimension (mm)
Control 7.2 6 0.5 9.0 6 0.3 8.7 6 0.4 8.8 6 0.3 8.8 6 0.5 8.9 6 0.3 8.7 6 0.4
Hypertension 7.3 6 0.4 7.3 6 0.8* 7.8 6 0.3* 7.2 6 1.0* 7.2 6 0.4* 7.8 6 0.2* 8.7 6 0.5
Midwall fractional shortening (%)
Control 25 6 2 20 6 2 19 6 4 16 6 4 19 6 4 14 6 3 14 6 3
Hypertension 24 6 2 18 6 1 15 6 5 13 6 2 17 6 4 17 6 3 15 6 2
LV mass (mg/g)
Control 2.53 6 0.31 2.47 6 0.15 2.18 6 0.29 2.17 6 0.18 2.00 6 0.17 2.28 6 0.15 2.20 6 0.22
Hypertension 2.51 6 0.28 2.90 6 0.25 3.09 6 0.22* 3.22 6 0.35* 3.83 6 0.53* 3.92 6 0.22* 4.29 6 0.33*
Values are expressed as mean 6 standard deviation. *p , 0.01 vs. control group at the same age. Heart rate was measured on the echo-Doppler recordings.
LV 5 left ventricular.
Figure 2. Evolving changes in Doppler indexes, E and E/A ratio in control
rats (broken line) and in hypertensive rats (solid line). Bars indicate values
of standard deviation. Asterisks indicate p , 0.01 versus control value at
corresponding age. E5 early diastolic filling wave; E/A ratio 5 the ratio of
peak early diastolic filling velocity and peak filling velocity at atrial
contraction.
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of LVH and associated diastolic dysfunction lead to the
transition to congestive heart failure, when MFVP changed
from relaxation abnormality to a pseudonormalized or
restrictive pattern. This change was not associated with
further impairment of LV relaxation but with stiffening of
the myocardium due to myocardial fibrosis and marked
LVH.
Diastolic filling abnormality in the initial stage. Initial
changes in MFVP included decreases in E and E/A ratio,
an increase in A and a prolongation of DT. These changes
are exactly the same as we predicted from the clinical
comparative studies in patients with hypertension. How-
ever, E/A ratio dropped below 1.0 only in one-third of
our rats studied, and there was no rat with an E/A ratio
of ,0.75, while E/A ratio is frequently ,1.0 in patients
with hypertension, and E/A ratio of ,1.0 is a common
definition of relaxation abnormality pattern in patients.
Normal value of E/A ratio is about 2.0 in rats, while it is
about 1.0 in humans in their fifties and about 1.3 in humans
in their forties (15). Thus, the difference in the normal value
of the E/A ratio is a likely explanation for the result that we
did not see MFVP with an E/A ratio of ,1.0 in hyperten-
sive rats as often as this is seen in patients with hyperten-
sion.
Slowed LV relaxation as assessed with an increase in tau
appeared to be a major contributor to the initial change in
MFVP. Although the change in another index of LV
relaxation, peak negative dP/dt, was different from that in
tau, the difference should be explained by the fact that peak
negative dP/dt is much more load-dependent that tau (16).
It is well known that diastolic filling is determined by
atrioventricular pressure gradient (17,18) and, therefore, is
regulated not only by LV relaxation but also by driving
pressure and LV operating stiffness or compliance (1–4).
For example, a decrease in driving pressure also causes the
similar change in MFVP, i.e., a relaxation abnormality
pattern. However, LVEDP was not altered at this stage in
our rats, and, therefore, this is an improbable mechanism.
Figure 3. Evolving changes in deceleration time (DT) in control rats
(broken line) and hypertensive rats (solid line). Bars indicate values of
standard deviation. Asterisk indicates p , 0.01 versus control value at
corresponding age.
Table 2. Hemodynamic and Pathological Parameters at the Ages of 7, 13 and 19 Weeks in Control and Hypertensive Rats
Group 7 Weeks
13 Weeks 19 Weeks
Control Hypertension Control Hypertension
Number 4 7 7 5 8
Systolic AoP (mm Hg) 114 6 5 117 6 5 223 6 12*† 134 6 9† 210 6 15*†
LVEDP (mm Hg) 6 6 3 6 6 2 8 6 1 7 6 2 21 6 4*†‡
Tau (ms) 18 6 3 19 6 3 25 6 4*† 20 6 3 26 6 3*†
1dP/dtmax (mm Hg/s) 7,196 6 290 6,797 6 698 8,002 6 1,182 7,828 6 716 6,261 6 1,539
2dP/dtmax (mm Hg/s) 7,677 6 1,408 8,872 6 1,508 8,640 6 1,238 9,785 6 1,277 7,122 6 1,623
Myocardial stiffness constant
Anterior wall 1.91 6 0.15 NA 1.98 6 0.08 1.77 6 0.19 2.55 6 0.30*†‡
Posterior wall 1.68 6 0.08 NA 1.89 6 0.13 1.75 6 0.15 2.41 6 0.20*†‡
Myocyte diameter (mm) 14.0 6 0.4 14.2 6 0.4 17.0 6 0.7*† 14.2 6 0.2 19.0 6 1.3*†
Area of fibrosis (%) 1.3 6 0.1 1.0 6 0.3 1.1 6 0.2 1.4 6 0.4 5.8 6 2.1*†‡
Values are expressed as mean 6 standard deviation. *p , 0.01 vs. control group at the same age; †p ,0.01 vs. data at 7 weeks; ‡p , 0.01 vs. data of hypertensive rats at 13 weeks.
2dP/dtmax 5 peak negative value of the first derivative of LV pressure; 1dP/dtmax 5 peak positive value of the first derivative of LV pressure; LV 5 left ventricular;
LVEDP 5 LV end-diastolic pressure; NA 5 no measurement; Systolic AoP 5 systolic aortic pressure; Tau 5 time constant of LV relaxation.
Figure 4. Tau and left ventricular end-diastolic pressure (LVEDP) at the
ages of 7, 13 and 19 weeks in control rats (broken line) and in hypertensive
rats (solid line). Bars indicate values of standard deviation. Asterisks
indicate p , 0.01 versus control value at corresponding age.
2336 Masuyama et al. JACC Vol. 36, No. 7, 2000
Mitral Flow in Hypertensive Rats December 2000:2333–8
An increase in afterload also works toward causing the
similar change in MFVP; however, because the changes in
afterload and in MFVP did not parallel each other in this
study, its contribution should be partial if present. In terms
of a passive component of LV diastolic property, we only
measured MSC. This index did not seem to be elevated at
this stage. It has been previously shown that the MSC,
end-diastolic elastic stiffness or both are not altered in
gradually developing experimental LVH (5,6,19). We cer-
tainly failed to assess LV compliance or stiffness at the
chamber level; however, chamber stiffness cannot have been
altered if we consider unchanged LVEDP and LV end-
diastolic diameter at this stage. An increase in tau was
observed at this stage even in the absence of myocardial
fibrosis in this study, which is consistent with the previous
study (5). Thus, LVH is only a possible constitutional or
pathological change of the myocardium at this stage.
Although LV mass progressively increased in a linear
fashion, MFVP did not change uniformly. The dissociation
of LV mass and MFVP indexes indicates that development
of LVH itself cannot be considered as a direct contributor to
the abnormal MFVP. In other words, not LVH itself but an
LVH-related change in diastolic function is a likely mech-
anism for the relaxation abnormality pattern in the initial
stage. The mechanism by which LVH alters diastolic
function is still unclear. Left ventricular hypertrophy is
associated not only with changes in quantity, such as
increases in LV mass and LV myocyte diameter, but also
with changes in quality such as isoform switching of actin,
myosin and other proteins. Left ventricular relaxation is
affected by the factors affecting inactivation, i.e., reuptake of
the myoplasmic activating calcium, which include metabolic
control by the coronary circulation and neurohumoral con-
trol (16). Any of these may well alter LVH development
and cause diastolic dysfunction without a constitutional
change in the myocardium. A reduction in relative mito-
chondrial volume that occurs early after pressure overload
may also be related (20).
Diastolic filling abnormality in the failing stage.
Changes in MFVP in the failing stage, i.e., a marked
increase in E, a decrease in A and a shortening of DT,
cannot be explained by the further change in LV relaxation
because tau did not change from 13 to 19 weeks. At this
stage increased LV stiffness appeared to be a most important
contributor to the abnormalities of MFVP. We certainly
failed to obtain an index of LV stiffness at the chamber level;
however, LV stiffness should be elevated at the failing stage
in our rats if a markedly elevated LVEDP in the absence of
LV enlargement is taken into consideration. Ohno et al.
(21) clearly showed that the transition of MFVP from a
relaxation abnormality to a restrictive pattern is closely
related with changes in LV stiffness in a model of pacing
induced heart failure. Their model is different from ours
because LV systolic dysfunction progressively occurred
along with diastolic dysfunction and because LV relaxation
abnormality paralleled changes in LV stiffness in their
model of dilated cardiomyopathy. In hearts with hyperten-
sion, however, LV systolic dysfunction is frequently mini-
mal even at the failing stage, and an increase in tau usually
precedes the changes in LV stiffness as observed in our
model. In addition, while neither myocardial hypertrophy
nor fibrosis is observed even at the failing stage in the pacing
model (22,23), both myocardial hypertrophy and fibrosis
were evident in our rats. The increase in LV stiffness, i.e.,
elevated LVEDP in the absence of LV enlargement, in our
rats should be at least partially explained by the increased
MSC due to myocardial fibrosis. Development of marked
LVH should have also contributed to the increase in LV
chamber stiffness independent of the change in MSC. Thus,
the pseudonormalized to restrictive pattern in the hearts
with hypertension should imply the presence of myocardial
constitutional changes such as myocardial hypertrophy and
fibrosis.
Study limitations. Two limitations are noted. First, our
anesthesia decreased heart rate by about 40% because resting
heart rate in rats is approximately 400 beats/min. Thus, the
values of hemodynamic and echo-Doppler indexes might
not reflect physiological conditions of the rat; however,
MFVP is not analyzable without negative chronotropic
anesthesia. Because the effects of anesthesia appeared ho-
mogeneous among the studied rats, we may safely use these
indexes for the interindividual comparisons. Second, we did
not measure left atrial function. Kono et al. (24) showed
that an increased workload imposed on the left atrial
myocardium and an eventual intrinsic left atrium dysfunc-
tion may account for the reduction of the left atrial
contribution to LV filling at the failing stage in a model of
heart failure, due to multiple sequential intracoronary em-
bolizations. The transition of MFVP from a relaxation
abnormality to a pseudonormalized and restrictive pattern
was so quick in our rats that intrinsic left atrium dysfunction
was unlikely to occur; however, changes in left atrial
function may have partially influenced the transition of
MFVP at the failing stage.
Conclusions. Development of pressure overload LVH was
associated with evolving changes in MFVP from normal to
relaxation abnormality pattern and, in turn, to a pseudonor-
malized pattern and finally to a restrictive pattern. The
evolving change was observed in a model of isolated
diastolic dysfunction, and, therefore, contribution of LV
systolic dysfunction to the evolving change should have been
small. It is not myocardial constitutional changes such as
myocardial hypertrophy or fibrosis themselves but LVH-
related changes in the active component of LV diastolic
function that directly contributed to the relaxation abnor-
mality pattern. The pseudonormalized to restrictive pattern
was associated with changes in LV stiffness due to LV
constitutional change, i.e., myocardial hypertrophy and
fibrosis. Analysis of the MFVP may be useful for following
not only functional but also constitutional changes in hearts
with hypertension.
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